SUMMARY Iliac crest trabecular bone volume and structure have been studied in bone biopsy specimens from 48 patients with classical or definite rheumatoid arthritis, none of whom had received steroids. Results were compared with those obtained from healthy controls matched for age and sex. The mean trabecular bone volume in female patients aged 34-50 years was significantly lower than in controls (p<O-O1); in male patients aged 34-5O years values were also lower than those in controls (mean (SD) 17-8 (3.2) v 22*4 (5.6)% total medullary volume), though this difference was not statistically significant. Values in older patients were similar to those of controls. The mean trabecular plate thickness was significantly lower in female patients in all three age groups when compared with the controls (p<0005, 0 05, and 0.005). Similar but non-significant changes were seen in male patients. The mean trabecular plate density, an index of trabecular number, and the mean trabecular plate separation showed no age related change in either male or female patients, in contrast with the female control group, in whom the mean trabecular plate density decreased and separation increased with age. These results suggest that non-steroid treated rheumatoid arthritis is associated with premature bone loss, the structural basis of which is trabecular thinning.
nection of the trabecular bone.'3 One approach to the study of bone microanatomical structure is to measure the mean trabecular plate thickness (MTPT); from this the mean trabecular plate separation (MTPS) and density (MTPD) can be calculated.'4 If bone loss is due to trabecular thinning the MTPT will be reduced, whereas the MTPS and MTPD will remain unchanged. Conversely, if bone loss by erosion predominates, MTPT will show little change while the MTPS will increase and the MTPD will decrease. In this study we have investigated trabecular bone mass in iliac crest biopsy specimens from 48 patients with chronic rheumatoid arthritis and have used the approach outlined above to study changes in bone microanatomical structure. To exclude steroid induced effects on bone only patients who had not received any systemic steroid therapy were studied.
Patients and methods
Forty eight patients with definite or classical rheumatoid arthritis,5 who had been enrolled into a trial of second line therapy, were studied. Thirty three were female, and the mean age of all patients was 53 years (range . The median duration of disease was four years (range . None had received systemic steroid therapy at any time, though a few had been given intra-articular steroids. No patient was receiving vitamin D or calcium therapy. Most patients were taking one or more of a variety of non-steroidal anti-inflammatory drugs; in addition, all were receiving second line therapy consisting of one of the following: penicillamine (maximum 500 mg/day) (n= 18), hydroxychloroquine (400 mg/day) (n=10), and auranofin (6 mg daily) or intramuscular sodium aurothiomalate (50 mg/month) maintenance (n=20).
Patients who were housebound or restricted to a wheelchair were excluded from the study, as were those with a history of gastrointestinal disease or surgery, liver disease, chronic renal disease, endocrine disease, or known metabolic bone disease. Informed written consent was obtained from each patient and permission for the study was granted by the local ethical committee. Disability was assessed by the Steinbroker16 and the London'7 methods.
CONTROLS
Control values for the indices measured in bone were obtained from age and sex matched control subjects, who underwent bone biopsy while under general anaesthetic for a minor surgical procedure. Details of these subjects have been published elsewhere. l'
For the purpose of analysis the patients and controls were divided into age groups, three for the women (34-50, 50-60, and 60-80 years) and two for the men (34- Reduced iliac crest trabecular bone volume in nonsteroid treated rheumatoid arthritis has not previously been reported, though two earlier studies also found a lower trabecular bone volume in biopsy specimens from patients with rheumatoid arthritis, some of whom were receiving steriod therapy.21 21 The reduction in mean trabecular plate thickness followed a pattern similar to that seen for the trabecular bone volume, trabecular thinning being most prominent in the young patients. Under normal circumstances, age related bone loss is associated mainly with trabecular thinning in men, whereas in women the predominant mechanism appears to be erosion through and removal ot trabeculae.2224 In the male patients with rheumatoid arthritis the pattern of bone loss was thus similar to that observed in normal aging males, though trabecular thinning occurred at an earlier age. In the female patients, however, the normal structural changes accompanying age related bone loss were replaced by trabecular thinning, and the decrease in mean trabecular plate density and increase in mean trabecular plate separation that would normally be seen in older women were not observed. This suggests that some factor, related either directly or indirectly to the disease -process, was able to over-ride the normal mechanisms of bone loss in women and to superimpose an alternative mechanism, namely trabecular thinning.
Although several studies have indicated that the prevalence of osteoporosis is increased in patients with rheumatoid arthritis, it is unclear whether this is solely due to disease related factors such as corticosteroid therapy and reduced physical activity or whether the disease process has a direct effect on bone mass. In the present study only patients who had not received steroid therapy were included, so that the well documented effects of steroids on bone could be excluded, and we were unable to show any relation between bone histomorphometric indices and assessments of functional ability. As bone loss is a slow process, however, occurring over many years, any assessment of the effects of inactivity must take into account the duration of disease and its course over that time; functional assessments made at one point in time may not be representative of past events nor do they necessarily reflect disease duration. Others have reported evidence that reduced physical activity is an important factor in the bone loss associated with rheumatoid arthritis.4 " Moreover, disease activity and duration, which are likely to be important determinants of functional ability, have been shown in some studies to be related to bone mass. Using a composite index of disease activity, Reid et al found a weak, but statistically significant correlation with total body calcium in non-steroid treated patients8; others, using single measurements of disease activity and localised skeletal measurements or radiology, have reported similar findings." 25 26 Attempts to correlate disease duration and bone mass have produced conflicting results, some studies demonstrating a significant correlation, ' 6 9 whereas others, including the present study, have been unable to show any relationship.4 25 26 The cellular pathophysiology of bone loss in rheumatoid arthritis is unknown. The clinical significance of generalised bone loss associated with rheumatoid arthritis has not been established; although there is evidence that the risk of osteoporotic fracture is increased in corticosteroid treated patients with rheumatoid arthritis, no such evidence exists for those not receiving steroid therapy, and it is unclear at present whether prophylaxis or treatment is indicated in the latter group. If subsequent studies do show an increased risk of fracture, knowledge of the structural and cellular mechanisms of bone loss may provide a rationale for the choice of therapeutic agent. Thus if the major part played by decreased bone formation is confirmed, a drug which stimulates osteoblasts, such as sodium fluoride, would seem appropriate. This drug increases trabecular width and thus may be most effective when bone loss is associated with trabecular thinning rather than when erosion and removal of trabeculae has destroyed the normal trabecular bone structure. In addition to therapeutic implications, knowledge of the cellular pathophysiology of bone loss associated with rheumatoid arthritis may lead to a better understanding of direct and indirect disease related factors which affect bone in this condition. 
